PepGen Inc. (PEPG)

PepGen Inc.'s stock price has experienced significant movements, including a 117.51% increase between January 10, 2025, and January 9, 2026, and a 350.79% increase over the last six months. Key events impacting the stock include positive clinical trial data for PGN-EDODM1, a public offering, analyst ratings and price target increases, the appointment of Joseph Vittiglio as Chief Business and Legal Officer, the issuance of a U.S. patent for its proprietary PGN-EDODM1 molecule, and the release of third quarter 2025 financial results.

Information regarding the demand seasonality for PepGen Inc.'s products and services is not readily available. Demand for its products, once approved, would likely be driven by medical need rather than traditional seasonal consumer patterns.

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurological diseases in the United States. The company's Enhanced Delivery Oligonucleotide (EDO) platform utilizes cell-penetrating peptides to enhance the uptake and activity of conjugated oligonucleotide therapeutics. PepGen's pipeline includes PGN-EDO51 (Phase 2 for DMD), PGN-EDODM1 (Phase 2 for DM1), PGN-EDO53 (preclinical for DMD), and PGN-EDO45 and PGN-EDO44 (preclinical stage programs).

PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts, United States. The company's clinical trials and development efforts are primarily focused on addressing diseases in the United States, with some multinational trials for PGN-EDODM1.

PepGen's brand reputation has been positively influenced by clinical advancements and analyst support. Positive results from the FREEDOM-DM1 trial have bolstered the company's standing, generating investor optimism. Analyst consensus ratings are generally positive, with a "Moderate Buy" rating based on 15 buy ratings, 0 hold ratings, and 0 sell ratings from analysts.

As of September 30, 2025, institutional investors hold 50.1% of PepGen Inc.'s stock, hedge funds hold 5.07%, VC/PE firms hold 36.4%, insiders hold 4.60%, and the general public holds 8.36%. Major institutional owners include RA Capital Management, L.P., Viking Global Investors Lp, Commodore Capital Lp, Vivo Capital, LLC, Point72 Asset Management, L.P., Bvf Inc/il, Laurion Capital Management LP, Vanguard Group Inc, Janus Henderson Group Plc and Rtw Investments, Lp.